:max_bytes(150000):strip_icc()/GettyImages-1970099302-41bb08e8e83543a4854b6ba0bab4c244.jpg?w=1920&resize=1920,1267&ssl=1 "AbbVie Stock Soars as Biotech Tops Sales Estimates, Raises Outlook | Global News Avenue")
AbbVie Stock Soars as Biotech Tops Sales Estimates, Raises Outlook
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1970099302-41bb08e8e83543a4854b6ba0bab4c244.jpg)
Key points
- In the fourth quarter of Abbvie’s revenue, it exceeded the higher sales forecast for Skyrizi and RinvoQ drug sales to treat inflammation.
- The demand for these two treatments offsets the continued decline in sales of HUMIRA, the previous heavy bomb medicine.
- ABBVIE has increased the long -term prospects of Skyrizi and RinvoQ.
abbvie (ABBV) Stocks are one of the biggest gains and losses S & P 500 On Friday morning, the biotechnology company released a sales that exceeded expected and put forward a strong guidance on its demand for the treatment of two drugs.
The company reported that revenue in the fourth quarter increased by nearly 6 % year -on -year to $ 15.1 billion, which was higher than the US $ 14.8 billion consensus estimate of an analyst at the visible Alpha survey. Adjustment Earnings per share (EPS) The prediction of $ 2.16 is lower than the forecast.
Skyrizi’s global sales have soared 58 % to US $ 3.78 billion, RinvoQ rose 46 % to 1.83 billion US dollars. Humira, which has lost market share due to ordinary competition, has declined (once the world’s best -selling drugs), which has been losing market share. HUMIRA sales gliding 49 % to 1.68 billion US dollars.
ABBVIE saw the sum of 2027 Skyrizi, RinvoQ’s sales exceeded $ 31B
The company has updated the long -term prospects of Skyrizi and RinvoQ. It is expected that the total sales in 2027 will exceed $ 31 billion. It was previously expected to exceed $ 27 billion. It added that Skyrizi’s Skyrizi revenue exceeded $ 20 billion and RinvoQ’s revenue exceeded $ 11 billion.
In addition, ABBVIe believes that the aesthetic income as of 2029 is a compound annual growth rate of height.
ABBVIE stocks, which soared about 8 % on Friday, increased by 15 % over last year.
TradingView
:max_bytes(150000):strip_icc()/GettyImages-1970099302-41bb08e8e83543a4854b6ba0bab4c244.jpg?w=1200&resize=1200,0&ssl=1&description=AbbVie+Stock+Soars+as+Biotech+Tops+Sales+Estimates%2C+Raises+Outlook+%7C+Global+News+Avenue){kind=link}